Related Experiment Video
Updated: Jan 17, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
IGF2BP3-mediated NTSR1 m6A methylation enhances irinotecan resistance and lung adenocarcinoma malignant progression
Hao Ding1, Xuan Zhu1, Yongquan Pan1
1Department of Respiratory Disease, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Rationale:
Neurotensin receptor 1 (NTSR1) is a high-affinity receptor for neurotensin. Its abnormal expression correlates with cancer development. However, its mechanisms in promoting the malignant progression and irinotecan resistance in lung adenocarcinoma (LUAD) remain unelucidated.
Methods:
NTSR1 expression in LUAD and its relationship with patients' prognosis were analyzed by bioinformatics analysis. NTSR1 expression in a human normal pulmonary epithelial cell line and LUAD cell lines was detected by RT-qPCR and Western blot. Cell proliferation ability was examined using the CCK-8 assay and colony formation assay. Flow cytometry was employed to detect cell cycle and apoptosis. The Transwell assay was undertaken to assess cell migration and invasion ability. DNA damage was detected using the comet assay and γ-H2AX immunofluorescence. Dot-blot and methylated RNA immunoprecipitation-qPCR were employed to examine m6A methylation levels. The interaction between IGF2 mRNA binding protein (IGF2BP3) and NTSR1 was verified by RNA immunoprecipitation and dual luciferase experiments. Immunohistochemistry was applied to analyze protein expression in mouse tumor tissues.
Measurements And Main Results:
NTSR1 was upregulated in LUAD cells, affecting patients' dismal overall survival. NTSR1 knockdown hindered cell proliferation, migration, and invasion, and reinforced apoptosis and irinotecan sensitivity. Mechanistically, IGF2BP3 interacted with NTSR1 and induced m6A methylation modification to enhance transcriptional stability, advancing the malignant progression of LUAD and irinotecan resistance. Additionally, NTSR1 knockdown enhanced the sensitivity of LUAD to irinotecan in mice and induced DNA damage.
Conclusions:
Overall, IGF2BP3-mediated NTSR1 m6A methylation expedites LUAD malignant progression and reinforces irinotecan resistance. Targeting this pathway may be an effective method for treating LUAD.
Insights
Neurotensin receptor 1 (NTSR1) promotes lung adenocarcinoma (LUAD) progression and Irinotecan resistance. Its stability is enhanced by IGF2BP3-mediated m6A methylation, suggesting a therapeutic target for LUAD treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Neurotensin receptor 1 (NTSR1) is implicated in cancer development, but its role in lung adenocarcinoma (LUAD) malignancy and Irinotecan resistance is unclear.
- Understanding the molecular mechanisms of NTSR1 in LUAD is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To investigate the role of NTSR1 in LUAD progression and Irinotecan resistance.
- To elucidate the underlying molecular mechanisms, including the involvement of IGF2BP3 and m6A methylation.
Main Methods:
- Bioinformatics analysis of NTSR1 expression and prognosis in LUAD.
- Quantitative real-time polymerase chain reaction (RT-qPCR) and western blot (WB) for NTSR1 expression.
- Cell proliferation, cell cycle, apoptosis, migration, and invasion assays.
- Comet assay and γ-H2AX immunofluorescence for DNA damage.
- MeRIP-qPCR for m6A methylation analysis.
- RNA immunoprecipitation (RIP) and dual luciferase assays for protein-RNA interaction.
- Immunohistochemistry (IHC) in mouse tumor models.
Main Results:
- NTSR1 is upregulated in LUAD, correlating with poor patient survival.
- NTSR1 knockdown inhibits LUAD cell proliferation, migration, and invasion, while enhancing apoptosis and Irinotecan sensitivity.
- IGF2BP3 interacts with NTSR1, promoting its transcriptional stability via m6A methylation.
- NTSR1 knockdown increases Irinotecan sensitivity and DNA damage in LUAD models.
Conclusions:
- IGF2BP3-mediated m6A methylation of NTSR1 accelerates LUAD progression and Irinotecan resistance.
- Targeting the IGF2BP3-NTSR1 pathway offers a potential therapeutic approach for LUAD.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

